Health Day - ONLINE EDITION
Posted: 05/19/2014 6:00 AM | Comments: 0
SUNDAY, May 18, 2014 (HealthDay News) -- A pair of drugs offers new hope to patients with a progressive, fatal disease that robs their breath by scarring the lungs, according to clinical trial results.
Both drugs, pirfenidone and nintedanib, appear to slow the advance of idiopathic pulmonary fibrosis, or IPF, an incurable and previously untreatable disease that causes tissue deep in the lungs to stiffen and scar.
Patients with IPF have a three-year survival rate of 50 percent, worse than most forms of cancer, said Dr. Gary Hunninghake, a lung disease specialist at Brigham and Women's Hospital in Boston.
Few live longer than five years past diagnosis, and the only way to save their lives is to replace their lungs.
"The long and short is, this is a pretty big deal in the field of IPF," Hunninghake said. "It isn't curing the disease. This certainly isn't the end of therapy for these patients. But the idea there is something we can do besides referring them to lung transplant is a pretty big deal."
Results from the two drug trials are published in the May 18 online issue of the New England Journal of Medicine. The issue also reports on a third IPF drug called acetylcysteine that proved ineffective in a clinical trial.
More than 100,000 Americans suffer from IPF, said Dr. David Lederer, co-author of the pirfenidone study. Most are between 50 and 70 years old. The disease starts with shortness of breath or a dry, hacking cough, but soon robs the person's body of the oxygen needed to move about or properly function.
Doctors don't know what causes IPF, although they suspect that smoking, genetics, certain viral infections or acid reflux could play a role in damaging the lungs, according to the U.S. National Institutes of Health.
Pirfenidone is approved for IPF treatment in other countries, but until now the U.S. Food and Drug Administration has denied approval based on mixed clinical trial results, Hunninghake said.
In this latest trial, doctors treated 555 IPF patients for one year with either pirfenidone or an inactive placebo. Pirfenidone produced a significant reduction in the rate of lung function decline, and improved patients' walking distance.
"This drug very clearly slowed down progression of the disease as measured by lung function, and seems to have an effect on mortality as well," said Lederer, co-director of the interstitial lung disease program at Columbia University Medical Center in New York City.
Researchers don't completely understand how pirfenidone works against IPF, Lederer said, but the drug seems to inhibit an important "growth factor" protein in the development of fibrosis. It also appears to have anti-inflammatory properties.
A second set of clinical trials tested the drug nintedanib against a placebo for one year in over 1,050 IPF patients.
Nintedanib also significantly reduced the rate of lung function decline, improving patients' ability to breathe. The drug specifically targets the "growth factor" proteins that cause lung tissue to stiffen and scar.
Gastrointestinal problems including diarrhea were the most common side effects of both medications, researchers reported.
The matter of approval now rests with the FDA. "Both of these trials were designed more than likely to get FDA approval after their publication," Hunninghake said.
Overall, the results of these trials will provide some much-needed encouragement to IPF patients. "It is an optimistic time for patients with fibrosis," said Dr. Gregory Cosgrove, chief medical officer for the Pulmonary Fibrosis Foundation.
The disease has been difficult to crack because animal models of lung fibrosis don't translate well to humans, he said. But the rapid advance of DNA sequencing has given researchers another avenue to understand how fibrosis works.
"It's been frustrating when we have not identified an effective therapy over the past 10 to 15 years," Cosgrove said. "But that degree of frustration has prompted the IPF community to really come together to support participation in clinical trials, and those trials have provided a foundation for these new advances."
For more information on idiopathic pulmonary fibrosis, visit the U.S. National Institutes of Health.
Have you found an error, or know of something we’ve missed in one of our stories? Please use the form below and let us know.
Having problems with the form?Contact Us Directly
A swimsuit shouldn't sink your self-esteem
Montreal superhospital receives first patients
Training basket: Grace Romund
Memo asks paramedics to pay for equipment
Judge clarifies decision on aboriginal case
Advocates worry health cuts are coming
City of Vancouver, federal minister at pot impasse
Hope floats as autistic kids learn to swim
Nurses says staff shortage puts patients at risk
Dr. Oz mounts spirited defence against critical letter
'Sugar Coated' explores health dangers of sweets
Private company to manage hospital services
Technician in fatal case forgot prison dialysis appointment
Nova Scotia menthol ban ignites debate
Health Tip: Manage Weight-Loss Goals
Health Tip: Dealing With Bedtime Anxiety
Health Highlights: April 22, 2015
Statins Carry Some Risk for Seniors, Study Suggests
Gene Therapy Shows Promise for Rare Immune Disorder
Depression Tied to Worse Outcomes for Black Patients With Heart Failure
Gene May Play Part in How Kids Respond to Asthma Meds: Study
For Earth Day, Turn Off the Faucet and the Ignition
Most Adults Don't Support Medical Marijuana for Kids, Poll Finds
Vaccine Spurs Immune Response to Fight Aggressive Cancers in Mice
FDA Weighs Tighter Regulation of Homeopathic Medicines
Ban Flavoring, Ads for E-Cigarettes, Doctors' Group Says
Ebola Treatment Shows Promise in Monkey Study
New Technology Tests Tumors Inside the Patient to Find Best Treatment
PCs warn the Ontario budget will add to debt
1 dead, 18 ill with botulism symptoms after church picnic
Wildrose to give 2 hours free parking at hospitals
Care aide suspended for speaking out: NDP
Demand for kidney transplants growing: report
Patients struggling to legally access pot: study
Liberals promise stability in health system
Lab matches 32 drug tests to wrong patients
Harsh winter affected blood donations
Family thanks donor who saved girl's life
Judge halts worker's comp claim for Ebola nurse Nina Pham